Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2019 | CLL14 trial thoughts

Constantine Tam • 20 Jun 2019
ICML 2019
Chronic Lymphocytic Leukemia Leukemia Chlorambucil Obinutuzumab Venetoclax
CLL14

Constantine Tam, MD, FRACP, FRCPA, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses his thoughts on the CLL14 trial (NCT02242942) of venetoclax-obinutuzumab among with untreated chronic lymphocytic leukemia (CLL) patients with a higher age or reduced fitness. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Constantine Tam

1:13
ALPINE trial update: zanubrutinib continues to show superior efficacy to ibrutinib in CLL
Constantine Tam • 11 Dec 2023
2:06
The potential of BGB-16673, a BTK degrader, for the treatment of R/R B-cell malignancies
Constantine Tam • 11 Dec 2023
1:52
SYMPATICO: Primary analysis results of ibrutinib plus venetoclax for patients with R/R MCL
Constantine Tam • 11 Dec 2023
2:36
Sonrotoclax plus zanubrutinib combination shows promise in treatment-naïve CLL/SLL
Constantine Tam • 11 Dec 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals